Since the majority of the ERα-negative breast cancer samples included in our cohort were also PR-negative and high grade [24,52,53], there was a limited capacity to find any association between expression of marker genes and those clinical variables, even when using the ERα-negative cell line MDA-MB-231. This evidence concerns the gene PGR and breast carcinoma.